Related Experiment Video

Updated: Aug 17, 2026

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix
09:11

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix

Published on: September 22, 2014

New therapies for heart failure: is thalidomide the answer?

P P Davey1, H Ashrafian

  • 1Nuffield Department of Medicine, Oxford University, John Radcliffe Hospital, Oxford, UK. patrick.davey@ndm.ox.ac.uk

QJM : Monthly Journal of the Association of Physicians
|May 29, 2000
PubMed

Insights

Advanced heart failure involves significant mortality. This study suggests thalidomide may help manage advanced heart failure by reducing tumor necrosis factor-alpha (TNF-alpha), a key inflammatory cytokine.

Area of Science:

  • Cardiology
  • Immunology
  • Pharmacology

Background:

  • Advanced heart failure is a significant clinical problem with high morbidity and mortality.
  • Disease progression theories evolved from hemodynamic factors to neuro-endocrine activation.
  • Recent research highlights the role of inflammatory cytokines, particularly tumor necrosis factor-alpha (TNF-alpha), in heart failure progression.

Purpose of the Study:

  • To explore the potential therapeutic role of thalidomide in managing advanced heart failure.
  • To investigate the link between TNF-alpha and heart failure progression.
  • To assess thalidomide's mechanism of action in reducing TNF-alpha levels.

Main Methods:

  • Review of current understanding of heart failure pathophysiology.
  • Analysis of the role of inflammatory cytokines, specifically TNF-alpha.
  • Examination of thalidomide's known therapeutic effects, particularly its impact on TNF-alpha.

Main Results:

  • Tumor necrosis factor-alpha (TNF-alpha) is implicated in the progression of advanced heart failure.
  • Thalidomide's primary therapeutic action involves the reduction of TNF-alpha levels.
  • A potential therapeutic strategy for advanced heart failure involves targeting TNF-alpha.

Conclusions:

  • Thalidomide's ability to reduce TNF-alpha suggests a potential role in advanced heart failure management.
  • Further investigation into thalidomide and its derivatives for heart failure treatment is warranted.
  • Targeting inflammatory pathways offers a promising avenue for novel heart failure therapies.

More Related Videos

Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy11:51

Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy

Published on: March 1, 2016

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...